Kymera Therapeutics (KYMR) Earnings Call Presentation

KT-621 Phase 1 Healthy Volunteer Trial Results - KT-621 demonstrated >90% STAT6 degradation in blood at doses above 1.5 mg [58, 112] - Complete STAT6 degradation was achieved in both blood and skin at doses ≥5 mg [58, 81, 87, 112] - KT-621 showed a favorable PK profile with rapid absorption (tmax of 2-4 hours) and a mean half-life of 9-36 hours [73] - The Phase 1 trial included 118 healthy volunteers in SAD and MAD groups [65] Th2 Biomarker Impact - KT-621 achieved up to 37% median TARC reduction [98] - KT-621 achieved up to 63% median Eotaxin-3 reduction [104] - IgE levels showed high variability and minimal changes, consistent with dupilumab effects in healthy volunteers [101, 103] Safety and Tolerability - KT-621 was well-tolerated with a safety profile undifferentiated from placebo [58, 107, 112] - No SAEs or severe AEs were reported in the healthy volunteer trial [108] Future Development - The company plans to initiate Phase 2b trials in Atopic Dermatitis (AD) and Asthma, starting in Q4 2025 and Q1 2026, respectively [21, 50] - The company has $775 million in cash and expects the runway to last into the first half of 2028 [16]